| Jun 6 |
Why Is Esperion Therapeutics (ESPR) Up 14.2% Since Last Earnings Report?
|
| May 23 |
Esperion's (ESPR) Drugs Get EU Nod for Lowering Heart Risk
|
| May 23 |
Esperion to Participate in Upcoming June Investor Conferences
|
| May 22 |
First-In-Class Cholesterol-Lowering Treatment NILEMDO® (NEXLETOL® in the U.S.) and Its Combination with Ezetimibe, NUSTENDI® (NEXLIZET® in the U.S.), Approved In Europe To Treat Hypercholesterolemia and Significantly Reduce Cardiovascular Risk
|
| May 20 |
Esperion's late stage trial of high cholesterol treatment met main goal
|
| May 20 |
Bempedoic Acid Met Primary Endpoint of Phase 3 Trial in Japan for the Treatment for Hypercholesterolemia
|
| May 20 |
Buy Esperion Therapeutics Despite An Abiding Skepticism Weighing On The Stock
|
